

Complex Injectable Market to Expand at a 11.3% CAGR by 2029, Reaching US \$30.38 Billion

The Business Research Company's Complex Injectable Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, October 10, 2025 /EINPresswire.com/ -- Get 20% Off All Global Market Reports With Code



ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

How Much Is The Complex Injectable Market Worth?

<u>The size of the complex injectable market</u> has seen a significant expansion in the past few years.



Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

> The Business Research Company

The market, which is expected to increase from \$17.70 billion in 2024 to \$19.77 billion in 2025, will have a Compound Annual Growth Rate (CAGR) of 11.7%. The substantial growth observed in the preceding years can be credited to factors such as the heightened occurrence of chronic ailments, a surge in the need for targeted biologic therapies, increasing use of self-administered devices, growth in oncology applications, and an increase in regulatory approvals for biosimilars.

In the forthcoming years, the size of the complex injectable market is forecasted to experience significant expansion,

reaching a market size of \$30.38 billion in 2029 with a compound annual growth rate (CAGR) of 11.3%. The expected growth during this forecast period is linked to several factors, including a greater emphasis on personalized medicine, higher healthcare spending, broader applications for autoimmune disorders, a preference among patients for less invasive treatments, and a heightened demand for self-administration devices. Notable trends projected for this forecast period encompass progress in biologic therapies, technological breakthroughs in drug delivery systems, advancements in nanotechnology aimed towards targeted delivery, improvements in

cold chain logistics, and evolution in injectable peptide and protein therapeutics.

Download a free sample of the complex injectable market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=28183&type=smp

What Are The Factors Driving The Complex Injectable Market?

The complex injectable market is anticipated to grow due to a consistent rise in chronic diseases. These are medical conditions which generally progress at a slow pace and necessitate continuous management. Factors contributing to the increase in chronic diseases include aging populations as older people are more prone to enduring health issues like diabetes, heart disease, and arthritis. Complex injectables facilitate the control of these diseases by administering specific medicines which help manage symptoms and decelerate the disease's progress. The Office for Health Improvement & Disparities (OHID), a public health agency based in the UK, predicts that the world's diabetic population will increment from 537 million adults in 2021 to 643 million by 2030. Consequently, the escalating occurrence of chronic diseases is spurring the advancement of the complex injectable market.

Who Are The Major Players In The Complex Injectable Market? Major players in the Complex Injectable Global Market Report 2025 include:

- Johnson & Johnson Pharmaceutical
- Merck & Co. Inc.
- Pfizer Inc.
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- Novo Nordisk
- Takeda Pharmaceutical Company Limited
- · Amgen Inc.
- Boehringer Ingelheim GmbH

What Are The Upcoming Trends Of Complex Injectable Market In The Globe? Top-tier companies in the drug delivery systems market are diligently working towards the development of improved drug delivery forms, such as autoinjector dosages. They aim to increase patient comfort, ensure compliance to treatment schedules, deliver drugs safely and accurately, and aid in the effective distribution of intricate biologic treatments. Autoinjector dosages are essentially ready-to-use, self-operated injection devices developed to safely and conveniently administer a specific dose of medicine. They are commonly utilized for biologics and other sophisticated therapies. For example, Taisho Pharmaceutical Co. Ltd., a generic drug producer based in Japan, in January 2024, launched a product named Nanozora 30 mg for subcutaneous injection. This innovative patient-friendly device is designed for effortless self-administration. To maximize safety, it is equipped with a needle-cover mechanism to avoid unintentional needle pricks. It provides a convenient monthly treatment option for patients with rheumatoid arthritis. Additionally, this broadens Taisho's range of treatment alternatives, adding

to its already available syringe formulation.

Which Segment Accounted For The Largest Complex Injectable Market Share? The complex injectable market covered in this report is segmented as

- 1) By Product Type: Monoclonal Antibodies, Gene Therapies, Vaccines Proteins and Peptides, Antibody-Drug Conjugates (ADCs)
- 2) By Therapeutic Area: Oncology, Diabetes, Autoimmune Disorders, Neurological Disorders, Cardiovascular Diseases, Infectious Diseases
- 3) By Route of Administration: Intravenous (IV), Subcutaneous (SC), Intramuscular (IM), Epidural, Intradermal
- 4) By Distribution Channel: Direct Sale, Pharmacies, eCommerce, Distributors, Wholesalers
- 5) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Healthcare, Research Institutions

Subsegment:

- 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies
- 2) By Gene Therapies: Somatic Gene Therapy, Germline Gene Therapy, Ex Vivo Gene Therapy, In Vivo Gene Therapy
- 3) By Vaccines, Proteins And Peptides: Recombinant Proteins, Synthetic Peptides, mRNA Vaccines, Viral Vector Vaccines
- 4) By Antibody Drug Conjugates: Cleavable Linker Antibody Drug Conjugates, Non-cleavable Linker Antibody Drug Conjugates, Cytotoxic Payload Antibody Drug Conjugates, Target-specific Antibody Drug Conjugates

View the full complex injectable market report:

https://www.thebusinessresearchcompany.com/report/complex-injectable-global-market-report

What Are The Regional Trends In The Complex Injectable Market?

For the year delineated in the Complex Injectable Global Market Report 2025, North America emerged as the dominant region. It is also projected that Asia-Pacific will witness the most rapid growth in the near future. All regions analyzed in this report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Complex Injectable Market 2025, By The Business Research Company

Generic Injectables Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-injectables-global-market-report

Facial Injectable Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

Patient Controlled Injectors Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/patient-controlled-injectors-global-market-report

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:

LinkedIn Facebook

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/856676730

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.